ReviewJournal of clinical medicine2023
Where Are We and Where to Next?-The Future of Perianal Crohn's Disease Management.
Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Assessment of outcomes in Crohn's disease: A systematic review of randomized clinical trials to inform a multiple outcome framework.United European gastroenterology journal · 2024Pooled it
- Tissue penetration of anti-tumour necrosis factor therapy in perianal fistulising Crohn's disease: a proof-of-concept study.European journal of gastroenterology & hepatology · 2026Article
- Multiomics analysis dissects the molecular foundation of perianal fistulas associated with Crohn's disease and of cryptoglandular origin.Journal of Crohn's & colitis · 2026Article
- What are the top 10 global research priorities for perianal Crohn's disease? The Global Perianal Crohn's Disease Priority Setting Partnership.Journal of Crohn's & colitis · 2026Article
- Time to classify: a narrative and scoping review of the old and the new classifications of perianal Crohn's disease.Techniques in coloproctology · 2025Article
- Perianal fistulizing Crohn's disease: Mechanisms and treatment options focusing on cellular therapy.World journal of gastroenterology · 2025Review
- Perianal Crohn's disease: Still more questions than answers.World journal of gastroenterology · 2024Article
- Long-Term Outcome of Surgery for Perianal Crohn's Fistula.Medicina (Kaunas, Lithuania) · 2024Article
- Surgical treatment of inflammatory bowel disease: From the gastroenterologist's stand-point.World journal of gastrointestinal surgery · 2024Article
- Challenges in IBD Research 2024: Novel Technologies.Inflammatory bowel diseases · 2024Review
- Tailoring therapy to the individuals of Crohn's disease.Science progressReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Perianal fistulizing Crohn's Disease (pCD) affects about 25% of patients with Crohn's Disease (CD). It remains a difficult entity to manage with a therapeutic ceiling of treatment success despite improving medical and surgical management. The refractory nature of the disease calls for an imminent need to better understand its immunopathogenesis and classification to better streamline our treatment options. In this article, we overview the current state of pCD management and discuss where the future of its management may lie.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.